Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Muscle Invasive Bladder Cancer × tislelizumab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 7 Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Neoplasms 3 Neoplasm Metastasis 3 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumor 2 Lymphoma, Large B-Cell, Diffuse 2 Carcinoma, Transitional Cell 2 Breast Neoplasms 2 Advanced Solid Tumors 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Triple Negative Breast Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Muscle Invasive Bladder Cancer 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡